APC inactivating and β-catenin stabilizing mutations have been described in SS [6, 7], but many other genetic, epigenetic, paracrine, and microenvironmental forces converge upon β-catenin stabilization and may provide alternate means of enabling SS18-SSX-driven oncogenesis. The gene discussed is SS18; the disease is synovial sarcoma.